Analysis of the risk and pre-emptive control of

2 viral outbreaks accounting for within-host

3 dynamics: SARS-CoV-2 antigen testing as a

4 case study

- 5
- 6 William S Hart^{1,2,*}, Hyeongki Park², Yong Dam Jeong^{2,3}, Kwang Su Kim^{2,3,4}, Raiki
- 7 Yoshimura², Robin N Thompson^{5,6,‡}, Shingo Iwami^{2,7,8,9,10,‡}
- 8

9 Affiliations:

- ¹Wolfson Centre for Mathematical Biology, Mathematical Institute, University of
- 11 Oxford, Oxford, OX2 6GG, UK
- ¹² ²interdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate
- 13 School of Science, Nagoya University, Japan
- ³Department of Mathematics, Pusan National University, Busan, South Korea
- ⁴Department of Science System Simulation, Pukyong National University, Busan,
- 16 South Korea.
- ⁵Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK
- ⁶Zeeman Institute for Systems Biology and Infectious Disease Epidemiology
- 19 Research (SBIDER), University of Warwick, Coventry, CV4 7AL, UK
- ²⁰⁷Institute of Mathematics for Industry, Kyushu University, Fukuoka, Japan.
- ²¹⁸Institute for the Advanced Study of Human Biology (ASHBi), Kyoto University, Kyoto,
- 22 Japan.
- ²³ ⁹Interdisciplinary Theoretical and Mathematical Sciences Program (iTHEMS), RIKEN,
- 24 Saitama, Japan.

- ¹⁰NEXT-Ganken Program, Japanese Foundation for Cancer Research (JFCR),
- 26 Tokyo, Japan. 13Science Groove Inc., Fukuoka, Japan.

27

- 28 *Correspondence to: <u>william.hart@maths.ox.ac.uk</u>
- ²⁹ [‡]These authors contributed equally to this work.

30 Abstract

31 In the era of living with COVID-19, the risk of localised SARS-CoV-2 outbreaks 32 remains. Here, we develop a multi-scale modelling framework for estimating the local 33 outbreak risk for a viral disease (the probability that a major outbreak results from a 34 single case introduced into the population), accounting for within-host viral dynamics. 35 Compared to population-level models previously used to estimate outbreak risks, our 36 approach enables more detailed analysis of how the risk can be mitigated through 37 pre-emptive interventions such as antigen testing. Considering SARS-CoV-2 as a 38 case study, we quantify the within-host dynamics using data from individuals with 39 omicron variant infections. We demonstrate that regular antigen testing reduces, but 40 may not eliminate, the outbreak risk, depending on characteristics of local 41 transmission. In our baseline analysis, daily antigen testing reduces the outbreak risk 42 by 45% compared to a scenario without antigen testing. Additionally, we show that 43 accounting for heterogeneity in within-host dynamics between individuals affects 44 outbreak risk estimates and assessments of the impact of antigen testing. Our results 45 therefore highlight important factors to consider when using multi-scale models to 46 design pre-emptive interventions against SARS-CoV-2 and other viruses.

47 Introduction

48	Following the widespread rollout of COVID-19 vaccines, countries worldwide
49	have adopted policies of "living with COVID-19" (for example, the UK removed its final
50	domestic restrictions in February 2022 (1)). Waves of COVID-19 cases continue to
51	occur (2), generated by factors including waning immunity (3,4) and the continued
52	evolution of the SARS-CoV-2 virus (5–7), although vaccines provide high levels of
53	ongoing protection against severe disease. Nonetheless, localised outbreaks, either in
54	geographical areas or in specific populations such as schools, universities and
55	workplaces, continue to cause disruption (for example, through student or staff
56	absence).
57	Mathematical modelling can be used to estimate the (local) outbreak risk, which
58	is defined as the probability that a major infectious disease outbreak results from a
59	single infection occurring within the population (8–12). While the outbreak risk can be
60	estimated by simulating a stochastic epidemic model a large number of times (and
61	calculating the proportion of simulations in which a large outbreak occurs), branching
62	process theory can also be used to derive outbreak risk estimates analytically (12). A
63	commonly used formula in the applied epidemic modelling literature (13–19) is
64	(Outbreak risk) = $1 - 1/R_0$ (whenever the basic reproduction number, $R_0 > 1$; when
65	$R_0 \leq 1$, the outbreak risk is zero). However, this formula relies on simplistic
66	assumptions, including each infected individual having constant infectiousness
67	throughout an exponentially distributed infectious period. Several studies have
68	therefore relaxed these assumptions, for example by considering a gamma-distributed
69	infectious period (14,17,20) and/or accounting for heterogeneity between age groups
70	(9,21,22).

71 In multi-scale epidemic modelling frameworks, within-host viral dynamics 72 models, which describe how the viral load of an infected host evolves over the course 73 of infection and can be calibrated to longitudinal individual data, are used to inform 74 population-level epidemiological models (23–25). One advantage of such approaches 75 is that they facilitate a detailed description of the impact of interventions, such as 76 antigen testing (26–28) or the use of antiviral drugs (29), which depend upon and/or 77 affect the within-host dynamics in a manner that cannot be fully captured in simple 78 population-level models. Multi-scale approaches have been applied to SARS-CoV-2 79 (26–33) and other pathogens including influenza (23.34) to generate outbreak 80 projections and test control interventions. However, multi-scale methods have not 81 previously been used to estimate the outbreak risk, or to analyse how the risk can be 82 mitigated through pre-emptive interventions.

83 In this study, we develop a multi-scale approach for calculating the outbreak 84 risk, accounting for within-host viral dynamics and heterogeneity in these dynamics 85 between individuals. We derive an equation satisfied by the outbreak risk under a 86 multi-scale model, and verify our analytically derived outbreak risk estimates using 87 simulations of an individual-based stochastic outbreak simulation model. Focussing 88 on the case study of SARS-CoV-2, we characterise the viral dynamics by fitting a within-host model (35-42) to data from 521 individuals with infections due to the 89 90 omicron variant (43). We first consider the outbreak risk in the absence of 91 interventions, before exploring the extent to which the outbreak risk can be mitigated 92 through regular rapid antigen testing of the entire local population. Additionally, we 93 analyse the impact of the reproduction number for local transmissions, the level of 94 transmission following detection, heterogeneity in within-host dynamics, and 95 asymptomatic infection, on the outbreak risk and the effectiveness of antigen testing.

- 96 Our results highlight that the impact of regular antigen testing on the local
- 97 SARS-CoV-2 outbreak risk is dependent on the regularity of testing, as well as the
- 98 exact population under consideration (including the level of vaccine- or
- 99 infection-acquired immunity) and the characteristics of the viral variant responsible for
- 100 infections. Based on our analysis, we expect antigen testing to reduce the outbreak
- 101 risk but not eliminate it completely. We stress that while SARS-CoV-2 is our focus
- 102 here, our general approach can be applied to other viruses in preparedness for future
- 103 outbreaks, epidemics and pandemics beyond COVID-19.

104 Results

105	Our multi-scale modelling framework for estimating outbreak risks and
106	analysing the impact of pre-emptive control is outlined in the context of SARS-CoV-2
107	and regular antigen testing in Figure 1. In our approach, a within-host model is first
108	fitted to individual infection data to estimate the viral load of infected hosts at each time
109	since infection, potentially accounting for heterogeneity in within-host dynamics
110	between different individuals (Figure 1A). Accounting for a reduced transmission risk
111	following detection, which may occur prior to symptom onset if regular antigen testing
112	is carried out (Figure 1B), the viral load profile(s) can be used to estimate the
113	infectiousness profile(s) (Figure 1C). The outbreak risk, following a single newly
114	infected individual arriving in an otherwise uninfected population, is then estimated
115	under a branching process transmission model incorporating the estimated
116	infectiousness profile(s) (Figure 1D). Specifically, we have analytically derived
117	equations satisfied by the outbreak risk assuming either homogeneous (Eq. (1) in
118	Methods) or heterogeneous (Eq. (2)) within-host dynamics (the derivations are
119	described in Supplementary Note 1). The effect on the outbreak risk of factors such
120	as the frequency of antigen testing can then be analysed.



121 122 Figure 1. Schematic illustrating our multi-scale approach for calculating the local SARS-CoV-2 123 outbreak risk, accounting for regular antigen testing. A (top right). By fitting a within-host model to 124 individual infection data, the temporal viral load profile(s) of infected individuals can be estimated, 125 potentially accounting for heterogeneity in within-host dynamics between individuals. B (bottom left). In 126 the absence of antigen testing, we assumed that infected individuals are detected upon symptom onset 127 (scenario 1). Regular antigen testing of the whole local population may facilitate detection before 128 symptoms (scenario 2), where the viral load profile can be used to estimate the probability of a positive 129 test result. Accounting for the frequency of testing, the probability of detection by each time since 130 infection can be calculated. C (middle right). The viral load profile(s) can then be used to estimate the 131 infectiousness profile(s) of infected individuals, accounting for a lower transmission risk following 132 detection, so earlier detection (e.g., when regular antigen testing takes place) leads to a suppressed 133 infectiousness profile. D (top left). Assuming a branching process transmission model incorporating the 134 estimated infectiousness profile(s) (the transmission trees next to C represent possible model 135 realisations either without or with regular antigen testing), we have analytically derived an equation 136 satisfied by the outbreak risk. The impact of the frequency of antigen testing on the outbreak risk can 137 then be assessed.

138 The SARS-CoV-2 local outbreak risk and the impact of regular antigen testing

Using nonlinear mixed effects modelling, we fitted a within-host viral dynamics
model (35–42) to data from 521 individuals with infections due to the omicron
SARS-CoV-2 variant (43). The temporal viral load profile of infected individuals, using
population estimates of within-host model parameters (Supplementary Table 1), is
shown in Figure 2A. Model fits to data from individual hosts are shown in

144 Supplementary Figure 1.

145 For simplicity, we initially demonstrated our multi-scale approach for estimating 146 the outbreak risk under the assumption of homogeneous within-host dynamics 147 (heterogeneous within-host dynamics are considered in **Figure 4**). First, we used the 148 viral load profile in Figure 2A to estimate the probability of detection by each time 149 since infection (Figure 2B). We considered scenarios both without regular population 150 antigen testing (so that infected individuals are only detected upon symptom onset), 151 and with regular antigen testing (with the detection probability accounting for 152 randomness in test timing and outcome). We then estimated the (expected) 153 infectiousness profile in each scenario, accounting for a reduction in the transmission 154 risk following detection, and averaging over different possible detection times in the 155 scenario with regular antigen testing (**Figure 2C**).

Outbreak risk estimates in the absence of regular antigen testing, obtained using either our multi-scale approach (using Eq. (1)) or the commonly used population-level estimate (which neglects within-host dynamics), $1 - 1/R_0$, are shown for a range of values of R_0 in **Figure 2D** (throughout this article, we always use R_0 to denote the basic reproduction number without regular antigen testing; we denote the reproduction number at the start of the outbreak but accounting for testing (if carried out) by $R_{0,eff}$). As would be expected, the outbreak risk increases with R_0 , while our

163 multi-scale method generally gives an outbreak risk higher than the standard

164 population-level estimate (when $R_0 \ge 1$).

165 We then used our multi-scale approach to explore the impact of regular 166 antigen testing on the outbreak risk. First, we estimated the proportion of 167 transmissions prevented from each infected individual, compared to a scenario in 168 which infected individuals are only detected upon symptom onset, under different 169 frequencies of testing (Figure 2E). We then calculated the outbreak risk in each case 170 (**Figure 2F**), assuming $R_0 = 1.5$ in the absence of testing (different R_0 values are 171 considered in Figure 3). Daily testing was here found to prevent 20% of transmissions 172 (Figure 2E), leading to an outbreak risk of 0.32 (Figure 2F), which is 45% lower than 173 the corresponding outbreak risk without testing (0.58). In comparison, testing every 174 two days was found to prevent only 13% of transmissions, giving an outbreak risk of 175 0.43. 176 To verify our results, we also used a discrete-time, individual-based, 177 stochastic outbreak simulation model to estimate the outbreak risk (Supplementary 178 **Figure 2**). There was relatively close agreement between estimates of the outbreak 179 risk between our analytic approach (blue line in **Figure 2F**) and the stochastic 180 simulations (red crosses). In **Supplementary Figure 3**, we considered the sensitivity 181 of our results to details of how we implemented antigen testing in our multi-scale 182 framework. We found a lower outbreak risk under frequent antigen testing (i.e., 183 antigen testing had a greater impact on the outbreak risk) when we assumed a 184 constant interval between antigen tests, compared to our baseline assumption of a 185 constant rate of testing (i.e., an exponentially distributed interval between tests, which 186 was more straightforward to implement in our analytic approach: **Supplementary** 187 Figure 3B).



188

189 Figure 2. Multi-scale estimation of the SARS-CoV-2 local outbreak risk and analysis of the 190 impact of regular antigen testing. A. Viral load profile using population estimates of within-host model 191 parameters (Supplementary Table 1). The symptom onset time is shown as a vertical grey dashed line 192 (note that the incubation period was estimated as part of the model fitting procedure), and the assumed 193 viral load threshold for infectiousness and antigen detection is shown as a horizontal black dashed line. 194 Note that we assumed a measurement error affecting antigen test outcomes, leading to the possibility of 195 a positive antigen test with true viral load below this threshold, and vice versa. B. Probability of detection 196 by each time since infection, both without regular antigen testing (blue) and with testing every two days 197 (orange dotted). C. Infectiousness profiles in the two scenarios, averaging over exact detection times of 198 different individuals in the scenario with antigen testing. **D**. The probability of a major outbreak without 199 antigen testing for different values of the basic reproduction number for local transmissions, R_0 , 200 comparing our multi-scale approach (blue) with the commonly used formula, $1 - 1/R_0$ (whenever 201 $R_0 > 1$; black dashed). **E**. The proportion of transmissions prevented from each infected individual by 202 regular antigen testing (compared to a scenario where infected individuals are only detected upon 203 symptom onset), $1 - R_{0,eff}/R_0$ (where $R_{0,eff}$ is the basic reproduction number accounting for testing), 204 for different values of the (mean) interval between tests. F. The outbreak risk for different values of the 205 (mean) interval between tests when $R_0 = 1.5$ in the absence of testing (results for other values of R_0 206 are shown in Figure 3C), comparing our analytic multi-scale approach (blue) with estimates obtained 207 using a discrete-time stochastic outbreak simulation model (see Supplementary Figure 2; red 208 crosses).

209 Effect of the local reproduction number and the extent of transmission

210 following detection

211 In **Figure 2F**, we considered the outbreak risk under antigen testing for a 212 single value of the basic reproduction number for local transmissions (in the absence 213 of testing), $R_0 = 1.5$. However, even for SARS-CoV-2, the R_0 value for local 214 outbreaks is likely to vary between time periods and local populations because of 215 factors including contact rates, viral evolution and existing immunity levels. Equivalent 216 results to those in Figure 2F for different R_0 values are therefore shown in Figure 3C. At R_0 values of 1.25 or below, we found daily antigen testing to be sufficient to reduce 217 218 the outbreak risk to zero (by reducing the reproduction number accounting for testing, 219 $R_{0.eff}$, to below one), whereas the estimated outbreak risk remains high even with 220 frequent antigen testing for large R_0 values.

221 We also explored the effect on our results of the relative transmission risk of 222 detected individuals, α_d (Figure 3DEF), with a lower α_d value corresponding to a 223 higher proportion of presymptomatic transmissions. Whereas in most of our analyses 224 we assumed a small, but positive, α_d value (reflecting that, for example, some 225 household transmission may occur following detection) (44), the blue curves in Figure 226 **3DEF** represent a scenario in which $\alpha_d = 0$. This may be relevant to specific 227 populations, such as workplaces, in which it may be possible to completely isolate 228 detected cases from the remainder of the population. In the scenario of no 229 transmission from detected individuals, antigen testing at arbitrarily high frequency 230 can theoretically prevent all transmissions that would otherwise occur (whereas in the 231 remainder of our analyses, only some proportion of presymptomatic transmissions 232 can be prevented), with testing every three days here being sufficient to reduce the 233 outbreak risk to zero (when $R_0 = 1.5$).



234

235 Figure 3. Effect of the local reproduction number and the extent of transmission following 236 detection on the outbreak risk under regular antigen testing. A. Infectiousness profiles without 237 regular antigen testing, assuming a basic reproduction number for local transmissions (in the absence 238 of testing) of $R_0 = 1.1$ (blue), 1.25 (red), 1.5 (orange), 2 (purple), or 2.5 (green). **B**. The proportion of 239 transmissions prevented from each infected individual by regular antigen testing (which is independent 240 of R_0). C. The outbreak risk for different values of the (mean) interval between antigen tests, plotted for 241 each R_0 value. **D**. Infectiousness profiles without regular antigen testing, assuming the relative 242 infectiousness of a detected host (compared to an undetected individual with the same viral load) is 243 $\alpha_d = 0$ (blue), 0.26 (red; the value used elsewhere in our analyses (44)), or 0.5 (yellow), with $R_0 = 1.5$ 244 in all cases. Under these α_d values, the proportions of presymptomatic transmissions (without regular 245 antigen testing) are 100%, 39% and 25%, respectively. E. The proportion of transmissions prevented 246 from each infected individual by regular antigen testing, for different values of the (mean) interval 247 between tests, plotted for each α_d value. F. The outbreak risk for different values of the (mean) interval 248 between tests, plotted for each α_d value.

Effect of heterogeneous within-host dynamics and asymptomatic infections

250 In order to present our multi-scale approach for calculating the outbreak risk in 251 a straightforward setting we have, up to this point, considered a scenario of identical 252 within-host viral dynamics for all infected individuals. However, in reality, within-host 253 dynamics differ between individuals. Our mixed effects within-host model fitting 254 approach has the advantage of facilitating estimation of the extent of heterogeneity in 255 within-host model parameters. We therefore conducted an analysis in which we 256 accounted for such heterogeneity when calculating the localised SARS-CoV-2 257 outbreak risk (Figure 4), using the generalised outbreak risk formulation in Eq. (2). 258 We found that accounting for heterogeneity in within-host dynamics leads to a 259 slightly smaller outbreak risk in the absence of regular antigen testing than in Figure 2 260 (Figure 4B). The model with heterogeneous within-host dynamics also gives a higher 261 proportion of transmissions prevented by regular antigen testing compared to the 262 homogeneous model (for each testing frequency considered; Figure 4C), contributing 263 to a greater difference in outbreak risk between the two models with regular antigen 264 testing than without (**Figure 4D**). For example, the outbreak risk when $R_0 = 1.5$ is 265 0.48 for the heterogeneous model without testing (0.58 for the homogeneous model), 266 and 0.17 with daily testing (0.32).

We also used the same outbreak risk formulation (Eq. (2)) to account for the possibility of entirely asymptomatic infections (i.e., some individuals remaining without symptoms throughout infection; **Figure 5**). In scenarios with a higher proportion of total transmissions generated by entirely asymptomatic infected hosts, the proportion of transmissions prevented by regular antigen testing was found to be higher (**Figure 5B**). This is because we assumed that asymptomatic hosts remain undetected throughout infection when antigen testing is not carried out, leading to a greater impact

274	of antigen testing on asymptomatic transmissions than on those from individuals who
275	develop symptoms. This effect is likely responsible for a lower outbreak risk at higher
276	proportions of asymptomatic transmissions when antigen testing takes place
277	frequently (Figure 5C). We note that an assumption that 0% of transmissions are
278	generated by the asymptomatic infected individuals in the population (blue curve in
279	Figure 5C) is different to assuming that there are no asymptomatic infected
280	individuals at all (black dashed curve). For example, in the former case, the outbreak
281	risk will be zero whenever the primary infected individual is asymptomatic, whereas in
282	the latter case the primary infected individual will not remain asymptomatic throughout
283	infection.



284

285 Figure 4. Effect of heterogeneity in within-host dynamics on the outbreak risk under regular 286 antigen testing. A. Example simulated infectiousness profiles for five infected individuals in the 287 absence of regular antigen testing, obtained by sampling within-host model parameters using the 288 estimates of fixed and random effects in Supplementary Table 1 and Supplementary Table 2, 289 respectively. The expected infectiousness profile (obtained by averaging the individual infectiousness 290 profiles of a large number of infected individuals) is shown as a black dotted curve. B. The probability of 291 a major outbreak without antigen testing for different values of the basic reproduction number, R_0 , 292 comparing our multi-scale approach, either assuming homogeneous within-host dynamics (blue) or 293 accounting for heterogeneity (red), and the commonly used formula, $1 - 1/R_0$ (black dashed). C. The 294 proportion of transmissions per infected individual prevented by regular antigen testing, for different 295 values of the (mean) interval between tests, plotted for the models with homogeneous (blue) and 296 heterogeneous (red) within-host dynamics. D. The outbreak risk for different values of the (mean) 297 interval between tests, for the same scenarios as in panel C.





300

Figure 5. Effect of asymptomatic infections on the outbreak risk under regular antigen testing.A. Infectiousness profiles for infected individuals who develop symptoms (blue) and those who remain

301 asymptomatic throughout infection (red), in the absence of regular antigen testing, assuming an overall

302 basic reproduction number, $R_0 = 1.5$, and that entirely asymptomatic hosts represent 20% of infected

303 hosts and generate 8% of transmissions (45). **B**. The proportion of transmissions per infected individual

304 prevented by regular antigen testing, for different values of the (mean) interval between tests, assuming

305 entirely asymptomatic infected hosts represent 20% of all infected hosts and generate 0% (blue), 8%

306 (red) or 20% (orange) of transmissions in the absence of antigen testing, and assuming no

307 asymptomatic infected hosts (black dotted). C. The outbreak risk for different values of the (mean)

308 interval between tests, for the same scenarios as in panel **B**.

309 Delayed and/or time-limited antigen testing

310 In most of our analyses of the effect of regular antigen testing on the local 311 SARS-CoV-2 outbreak risk, we focussed on a scenario in which testing is in place at 312 the time of virus introduction and continues indefinitely. However, we also generalised 313 our analytic outbreak risk derivation to scenarios where the infectiousness profile is 314 calendar time-dependent (Supplementary Note 4). This enabled us to explore how 315 the effectiveness of antigen testing is reduced if testing is introduced reactively 316 following the first infection occurring (**Supplementary Figure 4A**), and/or continues for only a limited time (Supplementary Figure 4B). We also conducted an analysis in 317 318 which we assumed a specified total number of tests to be available to each individual 319 (on average), and explored the optimal spacing of these tests to minimise the outbreak 320 risk (for example, 10 tests could be taken daily over 10 days, or once every two days 321 over 20 days; Supplementary Figure 4C), assuming reactive testing is introduced 322 when the first infected individual develops symptoms. These analyses therefore 323 demonstrate how antigen testing strategies can be optimised in settings with limited 324 testing resources. 325

326 Discussion

327 A key challenge for public health policy advisors is estimating the risk that 328 infectious disease cases introduced into a population will lead to a major local 329 outbreak. If the local outbreak risk can be calculated in populations with different 330 characteristics, this will enable limited surveillance and control resources to be 331 targeted effectively. In this article, we have presented a novel modelling framework for 332 estimating the local outbreak risk accounting for within-host viral dynamics. 333 To demonstrate our multi-scale approach in a concrete setting, we focussed 334 on the risk of local SARS-CoV-2 outbreaks. We used nonlinear mixed effects 335 modelling to fit a within-host model that has been used extensively to model 336 SARS-CoV-2 viral dynamics (35–42) to data from 521 individuals with omicron variant 337 infections (43). The nonlinear mixed effects approach enabled us to quantify the 338 variability in within-host dynamics between individuals which, in turn, could be used to 339 characterise heterogeneity in individual infectiousness profiles (describing how the 340 transmission risk varies during each infection). We then calculated the local outbreak 341 risk based on these data, assuming either homogeneous or heterogeneous 342 within-host dynamics, before testing the effect of regular antigen testing. We found 343 that regular antigen testing can mitigate, but not necessarily eliminate, the outbreak 344 risk, depending on the frequency of testing (for example, in **Figure 2** we estimated an 345 outbreak risk of 0.58 without testing, 0.43 with testing every two days, and 0.32 with 346 daily testing) and local transmission characteristics. 347 Regular antigen testing is an example of an intervention that can be modelled 348 in greater detail using a multi-scale approach than is possible using a simpler

349 population-level model. This is because both the probability of a positive test result,

and the impact of detection on transmission, are likely to depend on the viral load

351 profile, with the timing of testing important for determining the exact outcome.

352 Previous studies have used multi-scale models to analyse the effectiveness of antigen

testing for controlling an ongoing outbreak (26–28), but none of those studies

354 considered the impact of antigen testing on the outbreak risk.

355 Antigen testing was carried out at large scale in countries including the UK

356 (46) earlier in the COVID-19 pandemic, but (similarly to other non-pharmaceutical

357 interventions) has become less commonplace following the roll-out of vaccinations.

358 However, local outbreak prevention remains important in some specific populations in

the era of living with COVID-19, for example in care homes due to a high proportion of

360 vulnerable individuals, and our analyses of antigen testing have ongoing relevance to

361 such populations (the UK government continues to provide free tests to care homes

362 (47)). Furthermore, while we used within-host data for the omicron SARS-CoV-2

363 variant, our methodology and qualitative findings will be applicable if a future

364 SARS-CoV-2 variant, or other viral pathogen, necessitates wider use of

365 non-pharmaceutical interventions.

366 In the absence of antigen testing, accounting for heterogeneity in within-host 367 dynamics between different hosts generally gave rise to a lower outbreak risk estimate 368 compared to that obtained under the assumption of homogeneous within-host 369 dynamics, while the estimates using both versions of our multi-scale approach were 370 higher than a commonly used outbreak risk estimate that does not account for 371 within-host dynamics (13–19) (Figure 4B). These results are consistent with previous 372 comparisons of the outbreak risk between models with different infectious period 373 distributions (20) or offspring distributions (48), although previous studies did not 374 consider variations in infectiousness during infection. More variability in the total 375 number of transmissions generated by different individuals typically leads to a lower

outbreak risk since, for example, the probability of the primary infected individual
generating no transmissions will then be higher. We also found a greater impact of
antigen testing on transmission with heterogeneous than homogeneous within-host
dynamics (Figure 4C), which contributed to a bigger difference in outbreak risk
estimates between the heterogeneous and homogeneous models when antigen
testing is carried out (Figure 4D) than without testing.

382 Our results highlight that transmission characteristics depending on both the 383 virus and local population under consideration are important in determining the 384 outbreak risk and impact of antigen testing. In settings where the reproduction number 385 for local transmissions is high (e.g., in high-contact environments, or due to a new viral 386 variant or waning immunity), the outbreak risk may remain high even with a high 387 testing frequency, so that mitigations in addition to antigen testing would be required to 388 substantially reduce the risk. Conversely, we found antigen testing to be more 389 effective when a high proportion of transmissions are presymptomatic, such as in 390 schools and workplaces (provided symptomatic individuals are instructed to stay at 391 home). This is because population-wide testing enables infected individuals to be 392 detected before symptoms, thus preventing presymptomatic transmissions that would 393 otherwise have occurred. Similarly, when we accounted for entirely asymptomatic 394 infections (Figure 5), we found a lower outbreak risk under daily testing when a higher 395 proportion of transmissions are generated by asymptomatic infectors. 396 Like any modelling study, our analyses involved assumptions and 397 simplifications. We assumed that infectiousness scales with the logarithm of the viral

load (26,30), with a reduction in transmission risk upon detection (due to detected

individuals staying at home and/or isolating) (44,49,50). However, more complex

400 within-host models or relationships between viral load and infectiousness, or a delay

401 between detection and isolation, would be straightforward to implement in our 402 multi-scale modelling framework. We also assumed equal viral load thresholds for 403 infectiousness and for antigen test positivity, but this assumption could be relaxed to 404 explore how the outbreak risk under regular antigen testing depends on test 405 sensitivity, which may vary between tests developed by different manufacturers (51). While our focus here was rapid antigen testing, future work may compare the 406 407 effectiveness of antigen and PCR testing for reducing the outbreak risk, particularly 408 considering a trade-off between test sensitivity and turn-around time that has 409 previously been explored in the context of controlling an ongoing outbreak (28,30). 410 Our multi-scale approach for estimating the outbreak risk, accounting for 411 heterogeneous within-host viral dynamics, could be extended in numerous directions. 412 We considered a scenario involving a single infected individual arriving in a host 413 population early in their course of infection. However, it would be straightforward to 414 consider possibilities such as the primary infected individual entering the population 415 later in infection, and/or multiple infectious importations occurring. A future study may 416 also relate heterogeneity in within-host dynamics to specific characteristics such as 417 age, enabling the outbreak risk to be compared between local populations with 418 different structures. Other forms of heterogeneity, such as in susceptibility and/or 419 contact rates, could also be considered. Finally, going forwards, we plan to use the 420 mathematical results (**Supplementary Note 4**) underlying our analysis of reactively 421 introduced antigen testing (Supplementary Figure 4) to explore temporal changes in 422 the SARS-CoV-2 local outbreak risk, combining our multi-scale approach here with 423 previous work incorporating time-dependent susceptibility into outbreak risk estimates 424 (11) (for example, a booster vaccination campaign followed by waning immunity could 425 be considered).

426	In summary, we have developed a multi-scale modelling framework in which
427	within-host viral dynamics models can be used to inform estimates of the risk of
428	infectious disease outbreaks and to analyse the impact of pre-emptive control.
429	Applying our approach to estimate the risk of local SARS-CoV-2 outbreaks, we found
430	that regular antigen testing of the local population can reduce, but not eliminate, the
431	outbreak risk, depending on the frequency of testing as well as transmission
432	characteristics that are likely to vary temporally and between different populations.
433	Additionally, we found that it may be important to account for details such as
434	asymptomatic infection and heterogeneity in within-host dynamics to assess the
435	effectiveness of antigen testing accurately. We hope that this research will help to
436	guide pre-emptive control and mitigate the risk of outbreaks due to a range of viruses.
437	

438 Methods

439 Study data

- 440 We analysed published viral load data from 521 individuals with symptomatic
- infections due to the omicron SARS-CoV-2 variant (43). For each individual in the
- dataset, the results and timing (relative to a recorded symptom onset date, including
- some tests carried out prior to symptom onset) of at least three RT-qPCR tests were
- 444 available. The median number of tests per individual was 15. Viral load values
- 445 (converted from Ct values) were recorded for positive tests.
- 446

447 Within-host model and parameter estimation

448 We used a simple within-host model of SARS-CoV-2 viral dynamics (35–42), 449 given by

$$\frac{\mathrm{d}f}{\mathrm{d}\tau} = -bfV,$$
$$\frac{\mathrm{d}V}{\mathrm{d}\tau} = \gamma fV - \delta V,$$

450 where $f(\tau)$ and $V(\tau)$ denote, respectively, the proportion of uninfected target cells 451 (so that f(0) = 1) and viral load at time since infection τ . The parameters b, γ and δ 452 are the rate constant for virus infection, the maximum rate constant for viral replication, 453 and the death rate of infected cells, respectively.

We estimated the parameters b, γ and δ , in addition to the incubation period, τ_{inc} , by fitting the model to the viral load data using a nonlinear mixed effects modelling approach (amounting to a partial pooling of the data from each individual). Specifically, the value of the parameter vector, $\theta_j = (b_j, \gamma_j, \delta_j, \tau_{inc,j})$, for a given individual, j, was assumed to be of the form $\theta_j = \theta_{pop} \times e^{\xi_j}$ (where the operations are applied element-wise). Here, θ_{pop} is a fixed effect (referred to as the population parameter

460 value), and ξ_j is a random effect, assumed to be normally distributed with mean zero 461 and covariance matrix Ω . For simplicity, we assumed the random effects for different 462 parameters to be independent, with standard deviations ω_b , ω_γ , ω_δ and $\omega_{\tau_{inc}}$ (i.e., 463 $\Omega = \text{diag}(\omega^2 | \omega^2 | \omega$

463
$$\Omega = \operatorname{diag}(\omega_b^2, \omega_\gamma^2, \omega_\delta^2, \omega_{\tau_{\mathrm{inc}}}^2)).$$

464 In the parameter fitting procedure, we estimated both the fixed effects 465 (**Supplementary Table 1**; note that the subscript *pop* is suppressed) and the standard deviations of the random effects (Supplementary Table 2). In other words, we 466 467 characterised both the population (median) values of model parameters, as well as 468 variability in those parameters between individuals. The measurement error, σ , in 469 recorded values of the log viral load, was also estimated. These parameters were 470 estimated by using the Stochastic Approximation of the Expectation-Maximization 471 (SAEM) algorithm (52,53) to obtain the parameter values that maximise the likelihood 472 of the recorded viral load data. We accounted for left censoring of viral load data (i.e., a negative test result occurring at viral loads below the detection limit of 10^{2.66} 473 474 copies/ml) in the likelihood. Initial values of estimated parameters were changed 475 multiple times to confirm the robustness of parameter estimation and ensure a global 476 maximum of the likelihood was obtained. Additionally, we calculated best-fit estimates 477 (Empirical Bayes Estimates (53)) of within-host model parameters for each individual 478 host (**Supplementary Figure 1**). Fitting was implemented in MONOLIX version 479 2019R2 (53).

480

481 **Detection model**

482 We assumed that infected individuals could be detected in two possible ways:

1. By returning a positive antigen test.

484 2. By developing symptoms (we assumed previously undetected hosts to be

485 detected immediately upon symptom onset).

486 Supposing that an infected individual conducts an antigen test when their 487 instantaneous viral load is V, we assumed (similarly to previous work (40,42)) that a 488 positive test result occurs with probability $p_{\perp}(V) = \operatorname{Prob}(\hat{V} \ge V^*)$. Here, \hat{V} represents 489 a measured viral load, assumed to be normally distributed on the log scale 490 (independently of previous viral load measurements) such that $\log_{10}(\hat{V}) \sim$ $N(\log_{10}(V), \sigma^2)$; V^{*} is the detection limit (the choice of V^{*} is described in 491 492 **Supplementary Table 1**): and the value of the measurement error level, σ , was 493 assumed to be equal to the corresponding quantity that we estimated for PCR testing 494 (Supplementary Table 1). In other words, a positive test result was assumed to occur 495 whenever the measured viral load exceeds the detection limit. 496 In most of our analyses of regular antigen testing, we assumed an 497 exponentially distributed interval between successive tests, with mean T (i.e., a 498 constant rate of testing; the alternative scenario of a constant interval between tests is 499 considered in **Supplementary Figure 3B**). Under this assumption, the probability of 500 an infected individual being detected by time since infection τ is given by

$$p_d(\tau) = \begin{cases} 1 - \exp\left(-\frac{1}{T}\int_0^{\tau} p_+(V(x))dx\right), & \tau < \tau_{\rm inc}; \\ 1, & \tau \ge \tau_{\rm inc}; \end{cases}$$

where V(x) represents the viral load of the specified individual at time since infection x, and τ_{inc} their incubation period (τ_{inc} can be taken to be infinite to represent an entirely asymptomatic infection). This expression is derived in **Supplementary Note 1**.

505

506 Infectiousness model

507 The infectiousness profile of an undetected host, $\beta_u(\tau)$, at each time since

508 infection, τ , was assumed to depend on their viral load, $V(\tau)$, according to a

509 prescribed functional relationship. Specifically, we assumed (26,30)

$$\beta_{u}(\tau) = K \times \max\{\log_{10}(V(\tau)) - \log_{10}(V^{*}), 0\},\$$

so that only individuals with a viral load exceeding V^* are infectious. We assumed this infectiousness limit to be equal to the detection limit for antigen testing (i.e., in the absence of measurement errors, infected individuals will return a positive antigen test if and only if they are infectious at the time of testing). The choice of the scaling factor, K, is described below.

515 We assumed the effective infectiousness (accounting for behavioural factors) 516 of a detected individual at time since infection τ (where τ exceeds the time of 517 detection) to be a factor α_d times $\beta_u(\tau)$ (the choice of α_d , which lies between zero 518 and one, is described in **Supplementary Table 1**). In the absence of regular antigen 519 testing, the overall individual infectiousness profile is then

$$\beta(\tau) = \begin{cases} \beta_u(\tau), & \tau < \tau_{\rm inc}; \\ \alpha_d \beta_u(\tau), & \tau \ge \tau_{\rm inc}. \end{cases}$$

520 When regular antigen testing takes place, supposing the individual under 521 consideration has been detected by time since infection τ with probability $p_d(\tau)$, then 522 their expected infectiousness at time since infection τ (accounting for different 523 possible detection times) is

$$\beta(\tau) = \left[\alpha_d p_d(\tau) + \left(1 - p_d(\tau)\right)\right] \times \beta_u(\tau),$$

The scaling factor, *K*, in the expression for $\beta_u(\tau)$, was chosen to obtain a specified value of the basic reproduction number, R_0 , in the absence of regular antigen testing (except where otherwise specified, we took the default value $R_0 =$ 1.5). Specifically, if the expected infectiousness profile (averaging over individual

528 infectiousness profiles if the population is heterogeneous) is $\bar{\beta}(\tau)$, then we have (see

529 **Supplementary Note 2** in detail)

$$R_0 = \int_0^\infty \bar{\beta}(\tau) \, \mathrm{d}\tau$$

530

531 Outbreak risk

532 Here, we describe our approach for calculating the (local) outbreak risk (the 533 probability that a major outbreak results from a single newly infected individual being 534 introduced into an otherwise uninfected population) under the within-host, detection 535 and infectiousness models described above. A benefit of our approach is that we have 536 derived equations satisfied by the (local) outbreak risk analytically under a branching 537 process transmission model, assuming either homogeneous or heterogeneous 538 within-host dynamics between different infected individuals. These equations are 539 described below; derivations are given in **Supplementary Note 2**. The equations 540 were solved numerically, avoiding the need to run large numbers of stochastic model 541 simulations to estimate the local outbreak risk. However, we also verified our 542 analytically derived outbreak risk estimates against simulations of a discrete-time, 543 individual-based, stochastic epidemic model in Figure 2F (see Supplementary 544 Figure 2 and Supplementary Note 5 for details).

545

546 *Homogeneous population model*

547 First, we considered a simplified scenario in which each member of the 548 population is assumed to follow the same infectiousness profile, $\beta(\tau)$. In this case, an 549 analytic argument gives the following implicit equation for the outbreak risk:

 $p_{\text{outbreak}} = 1 - \exp(-R_{0,\text{eff}} \times p_{\text{outbreak}}), #(1)$

550 where the largest solution between 0 and 1 should be taken. Here, $R_{0.eff}$ is the 551 reproduction number at the start of the outbreak, accounting for regular antigen testing 552 (assumed to be in place at the time of pathogen introduction) if carried out, while we 553 use R_0 to refer specifically to the basic reproduction number in the absence of regular 554 antigen testing. This equation has previously been derived in the special case of 555 constant infectiousness during a fixed infectious period (18), but we show in 556 **Supplementary Note 2** that this equation is valid for any $\beta(\tau)$ (provided there is no 557 heterogeneity in infectiousness). We also emphasise that while this equation only 558 depends on $R_{0.eff}$, even in this simplified scenario our multi-scale approach enables 559 detailed analysis of how interventions such as antigen testing affect $R_{0,eff}$ and 560 therefore the outbreak risk, which cannot otherwise be captured easily. 561 We solved Eq. (1) numerically under the parameter values in **Supplementary** 562 **Table 1** (in particular, using population estimates of the within-host parameters b, γ , 563 δ and τ_{inc}) in order to estimate $p_{outbreak}$ in the absence of regular antigen testing. Then, we explored the effect of antigen testing on $p_{outbreak}$, for simplicity averaging 564 565 over the exact detection times of different individuals in most of our analyses. Of note, 566 in **Supplementary Figure 3A**, we found that explicitly accounting for heterogeneity in

568

567

569 *Heterogeneous population model*

We also conducted an analysis in which we accounted for heterogeneity in within-host dynamics between different individuals. In **Supplementary Note 2**, we show that if there are *n* population subgroups, with each infected individual in group *j* assumed to follow infectiousness profile $\beta_j(\tau)$, then the outbreak risk is the largest solution between 0 and 1 of

detection times had a very small effect on the $p_{outbreak}$ estimates.

$$p_{\text{outbreak}} = 1 - \sum_{j=1}^{n} a_j \times \exp(-R_j \times p_{\text{outbreak}}) \cdot \#(2)$$

575 Here, a_i represents the proportion of new infections that are in group j (at the start of 576 the epidemic and neglecting heterogeneity in contact rates between groups), which 577 simply corresponds to the proportion of the population in group *j* if there is no 578 difference in susceptibility between groups, while R_i gives the expected number of 579 transmissions generated by an infected host in group *j* over the course of infection (at 580 the start of the outbreak). We note that Eq. (2) includes as special cases most previous 581 outbreak risk estimates based on branching process approximations of 582 compartmental epidemic models (see **Supplementary Note 3**). 583 To account for heterogeneous within-host dynamics, we used the estimated 584 fixed (Supplementary Table 1) and random (Supplementary Table 2) effects to 585 generate synthetic viral load profiles and incubation periods for n = 10,000 infected 586 individuals. The infectiousness profile of each individual was obtained (averaging over 587 possible detection times when analysing regular antigen testing), and then Eq. (2) was 588 used to estimate the outbreak risk (taking $a_i = 1/n$ for each *j*). 589 We also used Eq. (2) when we accounted for entirely asymptomatic infections 590 (Figure 5). In Figure 5, we assumed that a proportion, $a_1 = 0.8$, of infected individuals develop symptoms, with the remaining proportion, $a_2 = 0.2$, remaining 591 592 asymptomatic throughout infection (45) (i.e., we took n = 2 in Eq. (2)). For simplicity, 593 we assumed no difference in within-host model parameters between entirely 594 asymptomatic hosts and those who develop symptoms, but instead considered 595 different possible values of the proportion of all transmissions arising from entirely 596 asymptomatic infectors (in the absence of regular antigen testing), given by

$$r_A = \frac{a_2 R_2}{a_1 R_1 + a_2 R_2} = \frac{a_2 x_A}{a_1 + a_2 x_A},$$

where $x_A = R_2/R_1$ represents the relative overall transmissibility of asymptomatic 597 598 infected hosts (where R_1 and R_2 represent the expected total number of 599 transmissions generated by each infected host who develops symptoms and by each 600 entirely asymptomatic infected host, respectively). Specifically, we considered r_A 601 values of 0, 0.08 and 0.2, which were obtained by scaling the infectiousness profiles of 602 entirely asymptomatic hosts to obtain corresponding x_A values of 0, 0.35 (the value 603 obtained by (45)) and 1, respectively. 604 Finally, we also used Eq. (2) when we accounted for variability in the exact 605 detection times of different infected individuals under regular antigen testing, 606 assuming either an exponentially distributed interval between tests (Supplementary 607 Figure 3A) or a fixed interval (Supplementary Figure 3B; in this case assuming each 608 infection time to be uniformly distributed between two testing times). In both cases, we 609 sampled the detection times of n = 10,000 hosts. 610 611 Delayed and/or time-limited regular antigen testing 612 In most of our analyses, we focussed on a scenario in which regular antigen 613 testing is already in place at the time of pathogen introduction and continues 614 indefinitely. However, we also considered scenarios in which testing is introduced

reactively after an infection occurs within the local population, and/or testing is only

carried out for a limited time period (Supplementary Figure 4). An equation for the

outbreak risk in this scenario is derived in **Supplementary Note 4**.

618 References

650

619	1.	UK Government. COVID-19 Response: Living with COVID-19. (2022). at
620		https://www.gov.uk/government/publications/covid-19-response-living-with-covid-19/
621		covid-19-response-living-with-covid-19#living-with-covid-19>
622	2.	World Health Organization. COVID-19 weekly epidemiological update (edition 123).
623		(2022). at
624		https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update2
625		1-december-2022>
626	3.	Lavine, J. S., Bjornstad, O. N. & Antia, R. Immunological characteristics govern the
627		transition of COVID-19 to endemicity. Science (1979) 371, 741–745 (2021).
628	4.	Barnard, R. C. et al. Modelling the medium-term dynamics of SARS-CoV-2
629		transmission in England in the Omicron era. Nat Commun 13, 4879 (2022).
630	5.	Dyson, L. et al. Possible future waves of SARS-CoV-2 infection generated by variants
631		of concern with a range of characteristics. Nat Commun 12, 5730 (2021).
632	6.	Thompson, R. N., Hill, E. M. & Gog, J. R. SARS-CoV-2 incidence and vaccine escape.
633		Lancet Infect Dis 21 , 913–914 (2021).
634	7.	Gog, J. R., Hill, E. M., Danon, L. & Thompson, R. N. Vaccine escape in a
635		heterogeneous population: insights for SARS-CoV-2 from a simple model. R Soc Open
636		<i>Sci</i> 8 , 210530 (2021).
637	8.	Thompson, R. N., Gilligan, C. A. & Cunniffe, N. J. Will an outbreak exceed available
638		resources for control? Estimating the risk from invading pathogens using practical
639		definitions of a severe epidemic. J R Soc Interface 17, 20200690 (2020).
640	9.	Lovell-Read, F. A., Shen, S. & Thompson, R. N. Estimating local outbreak risks and the
641		effects of non-pharmaceutical interventions in age-structured populations:
642		SARS-CoV-2 as a case study. <i>J Theor Biol</i> 535, 110983 (2022).
643	10.	Kaye, A. R., Hart, W. S., Bromiley, J., Iwami, S. & Thompson, R. N. A direct comparison
644		of methods for assessing the threat from emerging infectious diseases in seasonally
645		varying environments. J Theor Biol 548, 111195 (2022).
646	11.	Sachak-Patwa, R., Byrne, H. M., Dyson, L. & Thompson, R. N. The risk of SARS-CoV-2
647		outbreaks in low prevalence settings following the removal of travel restrictions.
648		Communications Medicine 1, 39 (2021).
649	12.	Southall, E. et al. A practical guide to mathematical methods for estimating infectious
650		disease outbreak risks. J Theor Biol 562, 111417 (2023).

651 13. Thompson, R. N., Gilligan, C. A. & Cunniffe, N. J. Detecting presymptomatic infection is 652 necessary to forecast major epidemics in the earliest stages of infectious disease 653 outbreaks. PLoS Comput Biol 12, e1004836 (2016). 654 14. Thompson, R. N., Jalava, K. & Obolski, U. Sustained transmission of Ebola in new 655 locations: more likely than previously thought. Lancet Infectious Diseases 19, 656 1058-1059 (2019). 657 15. Thompson, R. N., Thompson, C. P., Pelerman, O., Gupta, S. & Obolski, U. Increased 658 frequency of travel in the presence of cross-immunity may act to decrease the chance 659 of a global pandemic. Philosophical Transactions of the Royal Society B: Biological 660 Sciences 374, (2019). 661 Althaus, C. L., Low, N., Musa, E. O., Shuaib, F. & Gsteiger, S. Ebola virus disease 16. 662 outbreak in Nigeria: Transmission dynamics and rapid control. Epidemics 11, 80-84 663 (2015). 664 17. Craft, M. E., Beyer, H. L. & Haydon, D. T. Estimating the probability of a major outbreak 665 from the timing of early cases: an indeterminate problem? PLoS One 8, e57878 (2013). 666 18. Keeling, M. J. & Rohani, P. Modeling Infectious Diseases in Humans and Animals. 667 (Princeton University Press, 2008). doi:10.1016/s1473-3099(08)70147-6 668 19. Thompson, R. N. et al. The impact of cross-reactive immunity on the emergence of 669 SARS-CoV-2 variants. Front Immunol 13, 1049458 (2023). 670 20. Anderson, D. & Watson, R. On the spread of a disease with gamma distributed latent 671 and infectious periods. Biometrika 67, 191-198 (1980). 672 21. Nishiura, H., Cook, A. R. & Cowling, B. J. Assortativity and the probability of epidemic 673 extinction: A case study of pandemic influenza A (H1N1-2009). Interdiscip Perspect 674 Infect Dis 2011, (2011). 675 22. Yates, A., Antia, R. & Regoes, R. R. How do pathogen evolution and host heterogeneity 676 interact in disease emergence? Proceedings of the Royal Society B: Biological 677 Sciences 273, 3075-3083 (2006). 678 23. Hart, W. S., Maini, P. K., Yates, C. A. & Thompson, R. N. A theoretical framework for 679 transitioning from patient-level to population-scale epidemiological dynamics: influenza 680 A as a case study. J R Soc Interface 17, 20200230 (2020). 681 24. Childs, L. M. et al. Linked within-host and between-host models and data for infectious 682 diseases: a systematic review. PeerJ7, e7057 (2019).

- 683 25. Garira, W. A complete categorization of multiscale models of infectious disease
- 684 systems. *J Biol Dyn* **11**, 378–435 (2017).
- Larremore, D. B. *et al.* Test sensitivity is secondary to frequency and turnaround time
 for COVID-19 screening. *Sci Adv* 7, eabd5393 (2021).
- 687 27. Whitfield, C. A. & Hall, I. Modelling the impact of repeat asymptomatic testing policies
 688 for staff on SARS-CoV-2 transmission potential. *J Theor Biol* 557, 111335 (2023).
- 689 28. Forde, J. E. & Ciupe, S. M. Quantification of the tradeoff between test sensitivity and
- test frequency in a COVID-19 epidemic—a multi-scale modeling approach. *Viruses* 13,
 457 (2021).
- 692 29. Torneri, A. *et al.* A prospect on the use of antiviral drugs to control local outbreaks of
 693 COVID-19. *BMC Med* 18, 191 (2020).
- 694 30. Larremore, D. B., Toomre, D. & Parker, R. Modeling the effectiveness of olfactory
 695 testing to limit SARS-CoV-2 transmission. *Nat Commun* 12, 3664 (2021).
- Goyal, A., Reeves, D. B., Fabian Cardozo-Ojeda, E., Schiffer, J. T. & Mayer, B. T. Viral
 load and contact heterogeneity predict SARS-CoV-2 transmission and super-spreading
 events. *Elife* 10, e63537 (2021).
- Goyal, A. *et al.* Slight reduction in SARS-CoV-2 exposure viral load due to masking
 results in a significant reduction in transmission with widespread implementation. *Sci Rep* 11, 11838 (2021).
- 33. Goyal, A., Reeves, D. B. & Schiffer, J. T. Multi-scale modelling reveals that early
 super-spreader events are a likely contributor to novel variant predominance. *J R Soc Interface* 19, (2022).
- Murillo, L. N., Murillo, M. S. & Perelson, A. S. Towards multiscale modeling of influenza
 infection. *J Theor Biol* 332, 267–290 (2013).
- 35. Ikeda, H. *et al.* Improving the estimation of the death rate of infected cells from time
 course data during the acute phase of virus infections: application to acute HIV-1
 infection in a humanized mouse model. *Theor Biol Med Model* **11**, 22 (2014).
- 710 36. Kim, K. S. *et al.* A quantitative model used to compare within-host SARS-CoV-2,
- 711 MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and
 712 treatment of SARS-CoV-2. *PLoS Biol* **19**, e3001128 (2021).
- 713 37. Ejima, K. *et al.* Estimation of the incubation period of COVID-19 using viral load data.
 714 *Epidemics* 35, 100454 (2021).

715	38.	Iwanami, S. et al. Detection of significant antiviral drug effects on COVID-19 with
716		reasonable sample sizes in randomized controlled trials: A modeling study. PLoS Med
717		18 , e1003660 (2021).
718	39.	Jeong, Y. D. et al. Revisiting the guidelines for ending isolation for COVID-19 patients.
719		<i>Elife</i> 10 , e69340 (2021).
720	40.	Jeong, Y. D. et al. Safely return to schools and offices: early and frequent screening
721		with high sensitivity antigen tests effectively identifies COVID-19 patients. medRxiv
722		2021.10.08.21264782 (2021). doi:10.1101/2021.10.08.21264782
723	41.	Ejima, K. et al. Estimation of timing of infection from longitudinal SARS-CoV-2 viral load
724		data: mathematical modelling study. BMC Infect Dis 22, 656 (2022).
725	42.	Jeong, Y. D. et al. Designing isolation guidelines for COVID-19 patients with rapid
726		antigen tests. Nature Communications 2022 13:1 13, 4910 (2022).
727	43.	Hay, J. A. et al. Quantifying the impact of immune history and variant on SARS-CoV-2
728		viral kinetics and infection rebound: a retrospective cohort study. Elife 11, e81849
729		(2022).
730	44.	Hart, W. S. et al. Generation time of the alpha and delta SARS-CoV-2 variants: an
731		epidemiological analysis. Lancet Infect Dis 22, 603–610 (2022).
732	45.	Buitrago-Garcia, D. et al. Occurrence and transmission potential of asymptomatic and
733		presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis.
734		<i>PLoS Med</i> 17 , e1003346 (2020).
735	46.	Torjesen, I. Covid-19: How the UK is using lateral flow tests in the pandemic. BMJ 372,
736		n287 (2021).
737	47.	UK Government. COVID-19 testing in adult social care. (2022). at
738		https://www.gov.uk/government/publications/coronavirus-covid-19-testing-for-adult-s
739		ocial-care-settings/covid-19-testing-in-adult-social-care>
740	48.	Lloyd-Smith, J. O., Schreiber, S. J., Kopp, P. E. & Getz, W. M. Superspreading and the
741		effect of individual variation on disease emergence. Nature 438, 355–359 (2005).
742	49.	Hart, W. S., Maini, P. K. & Thompson, R. N. High infectiousness immediately before
743		COVID-19 symptom onset highlights the importance of continued contact tracing. Elife
744		10 , e65534 (2021).
745	50.	Hart, W. S. et al. Inference of the SARS-CoV-2 generation time using UK household
746		data. <i>Elife</i> 11 , e70767 (2022).

- 747 51. Bekliz, M. et al. Analytical Sensitivity of Eight Different SARS-CoV-2 Antigen-Detecting
- 748 Rapid Tests for Omicron-BA.1 Variant. *Microbiol Spectr* **10**, e00853-22 (2022).
- 52. Kuhn, E. & Lavielle, M. Maximum likelihood estimation in nonlinear mixed effects
- 750 models. Comput Stat Data Anal **49**, 1020–1038 (2005).
- 751 53. Lixoft. Monolix documentation. at <https://monolix.lixoft.com/>
- 752

753 Acknowledgements

- We would like to thank Philip Maini for helpful comments on the manuscript. W.S.H.
- acknowledges funding by the Engineering and Physical Sciences Research Council
- via a Doctoral Prize (grant number EP/W524311/1) and by the Japan Society for the
- 757 Promotion of Science via an International Research Fellowship (short-term
- 758 Predoctoral Fellowship). This study was supported in part by a Grant-in-Aid for
- 759 Transformative Research Areas A 22H05215 (to S.I.), JSPS Scientific Research
- 760 (KAKENHI) B 18H01139 (to S.I.), 16H04845 (to S.I.), Scientific Research in Innovative
- 761 Areas 20H05042 (to S.I.); AMED CREST 19gm1310002 (to S.I.); AMED Development
- of Vaccines for the Novel Coronavirus Disease, 21nf0101638s0201 (to S.I.); AMED
- 763 Japan Program for Infectious Diseases Research and Infrastructure,

764 20wm0325007h0001 (to S.I.), 20wm0325004s0201 (to S.I.), 20wm0325012s0301 (to

- 765 S.I.), 20wm0325015s0301 (to S.I.); AMED Research Program on HIV/AIDS
- 766 22fk0410052s0401 (to S.I.); AMED Research Program on Emerging and
- 767 Re-emerging Infectious Diseases 20fk0108140s0801 (to S.I.), 21fk0108428s0301 (to
- S.I.); AMED Program for Basic and Clinical Research on Hepatitis 21fk0210094 (to
- 769 S.I.); AMED Program on the Innovative Development and the Application of New
- 770 Drugs for Hepatitis B 22fk0310504h0501 (to S.I.); AMED Strategic Research Program
- for Brain Sciences 22wm0425011s0302; JST MIRAI JPMJMI22G1 (to S.I.); Moonshot
- 772 R&D JPMJMS2021 (to S.I.) and JPMJMS2025 (to S.I.); Shin-Nihon of Advanced
- 773 Medical Research (to S.I.); SECOM Science and Technology Foundation (to S.I.).

774

775 Author contributions

- W.S.H. and S.I. conceptualised the study. All authors developed the methodology.
- W.S.H. and H.P. wrote the model code and conducted the computational analyses.
- 778 S.I. and R.N.T. supervised the research. W.S.H. wrote the initial manuscript draft. All
- authors reviewed and edited the manuscript.

780

781 Competing interests

782 The authors declare no competing interests.